Trials / Completed
CompletedNCT00641953
IMX-150 Cream for Diabetic Neuropathy
A Randomized, Phase II, Multi-Center, Double-Blind, Placebo-Controlled, Dose-Response Study of an Aqueous Topical Formulation of Nitroglycerin, IMX-150, in the Treatment of Pain in Diabetic Peripheral Neuropathy of the Feet
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 155 (actual)
- Sponsor
- Procris Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to compare the effectiveness of two different dose of IMX-150 to that of placebo (non-active) in the treatment of diabetic peripheral neuropathy pain of the feet.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | IMX-150 | (0.3%) 0.5g topically BID to each foot for 4 weeks |
| DRUG | IMX-150 | (0.6%) 0.5g topically BID to each foot for 4 weeks |
| DRUG | Placebo | 0.5 g topically BID to each foot for 4 weeks |
Timeline
- Start date
- 2007-08-01
- Primary completion
- 2008-03-01
- Completion
- 2008-03-01
- First posted
- 2008-03-24
- Last updated
- 2008-06-17
Locations
7 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00641953. Inclusion in this directory is not an endorsement.